People: Allos Therapeutics Inc (ALTH.O)

ALTH.O on Consolidated Issue listed on NASDAQ Global Market

6.94USD
9 Feb 2010
Price Change (% chg)

$0.07 (+1.02%)
Prev Close
$6.94
Open
--
Day's High
$7.03
Day's Low
$6.84
Volume
435,398
Avg. Vol
1,103,760
52-wk High
$8.79
52-wk Low
$5.34

view people for:

Summary

Name Age Since Current Position
Hoffman, Stephen 55 2001 Chairman of the Board
Berns, Paul 42 2006 President, Chief Executive Officer, Director
Clark, David 40 2007 Principal Financial Officer, Vice President - Finance, Treasurer, Assistant Secretary
Caruso, James 50 2006 Executive Vice President, Chief Commercial Officer
Graboyes, Marc 39 2008 Senior Vice President, General Counsel, Secretary
Bennett, Bruce 58 2008 Vice President - Pharmaceutical Operations
Hen, Stewart 42 2005 Director
Leff, Jonathan 40 2005 Director
Lynch, Timothy 39 2005 Director
Latts, Jeffrey 61 2007 Director
Stout, David 55 2009 Director
» Insider Trading

Biographies

Name Description
Hoffman, Stephen Dr. Stephen J. Hoffman, Ph.D., M.D. is the Chairman of the Board of Allos Therapeutics, Inc. Dr. Hoffman has served as a Managing Director of Skyline Ventures, a venture capital firm, since May 2007. From January 2003 to March 2007, Dr. Hoffman was a General Partner of TechnoVenture Management, a venture capital firm. He has served as a member of the Board of Directors since 1994 and as the Company's Chairman of the Board since December 2001. From July 1994 to December 2001, Dr. Hoffman served as the Company's President and Chief Executive Officer. Prior to that, from inception to 1994, Dr. Hoffman served as a consultant to the Company's investor group. From 1990 to 1994, he completed a fellowship in clinical oncology and a residency/fellowship in dermatology, both at the University of Colorado. Dr. Hoffman was the scientific founder of Somatogen Inc., a biopharmaceutical company, where he held the position of Director of Corporate Research and Vice President of Science and Technology from 1987 to 1990. Dr. Hoffman received his Doctorate in Philosophy in bio-organic chemistry from Northwestern University and his Doctorate of Medicine from the University of Colorado School of Medicine.
Berns, Paul Paul L. Berns has served as President and Chief Executive Officer, and as a member of the Board of Directors of Allos Therapeutics, Inc., since March 2006. Prior to joining the Company, Mr. Berns was a self-employed consultant to the pharmaceutical industry from July 2005 to March 2006. From June 2002 to July 2005, Mr. Berns was President, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in 2005. Prior to that, from 2001 to 2002, Mr. Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories, a pharmaceutical company. From 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals-Knoll, a pharmaceutical company, and from 1990 to 2000, Mr. Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company, a pharmaceutical company. Mr. Berns is a director of XenoPort, Inc. Mr. Berns received a Bachelor of Science in Economics from the University of Wisconsin.
Clark, David David C. Clark has served as Vice President, Finance of Allos Therapeutics, Inc. since February 2007, as Principal Financial Officer since March 2006 and as the Company's Treasurer since May 2004. Mr. Clark also served as the Company's Corporate Controller from May 2004 to April 2007. He has served as the Company's Assistant Secretary since October 2004 and served as Secretary from May 2004 to October 2004. From March 2000 to October 2003, Mr. Clark held several positions at Seurat Company (formerly XOR Inc.), a technology company, serving most recently as Vice President of Finance and Chief Financial Officer. From 1992 to March 2000, Mr. Clark worked in the audit practice of PricewaterhouseCoopers LLP. Mr. Clark is a Certified Public Accountant and received a Masters of Accountancy and a Bachelor of Science in Accounting from the University of Denver.
Caruso, James James V. Caruso has served as Executive Vice President and Chief Commercial Officer of Allos Therapeutics, Inc. since June 2006. Prior to joining the Company, Mr. Caruso was a self-employed consultant to the pharmaceutical industry from July 2005 to June 2006. From June 2002 to July 2005, Mr. Caruso was Senior Vice President, Sales and Marketing at Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in 2005. Prior to that, from June 2001 to June 2002, Mr. Caruso was a Vice President of Specialty Sales at Novartis, a pharmaceutical company. From 2000 to 2001, he served as Vice President, Sales of BASF Pharmaceuticals-Knoll, a pharmaceutical company, and from 1988 to 2000, Mr. Caruso held various positions, including senior management roles, at Bristol-Myers Squibb Company, a pharmaceutical company. Mr. Caruso earned his Bachelor of Science in Finance from the University of Nevada.
Graboyes, Marc Marc H. Graboyes has served as Senior Vice President, General Counsel and Secretary of Allos Therapeutics, Inc. since February 2008, and served as the Company's Vice President, General Counsel and Secretary from October 2004 to January 2008. From 2000 to October 2004, Mr. Graboyes was an attorney with Cooley Godward LLP, where he practiced corporate and securities law and served as outside counsel to the Company. Prior to joining Cooley Godward, Mr. Graboyes practiced corporate and securities law with several other national law firms. Mr. Graboyes earned his Juris Doctor from the University of Colorado School of Law and received his Bachelor of Science in Entrepreneurship & Small Business Management from the University of Colorado at Boulder.
Bennett, Bruce Bruce K. Bennett has served as the Vice President, Pharmaceutical Operations of Allos Therapeutics, Inc. since January 2008. Prior to joining the Company, Mr. Bennett was a self-employed consultant to the biotechnology and pharmaceutical industries from 2006 to January 2008. From 2002 to 2006, Mr. Bennett served as Vice President, Manufacturing at La Jolla Pharmaceuticals. Prior to La Jolla, Mr. Bennett served as Vice President, Operations at Provasis Therapeutics from 2000 to 2002, and as Vice President, Operations, RA/QA/QC and Commercial Development at Via Medical Corporation from 1997 to 2000. From 1987 to 1997, Mr. Bennett served as a senior operations executive of various pharmaceutical, biotechnology and other companies. Mr. Bennett earned his Masters of Business Administration from Pepperdine University and his Bachelor of Science in Industrial Technology from California State University, Long Beach.
Hen, Stewart Stewart Hen has served as a member of the Board of Directors of Allos Therapeutics, Inc. since March 2005. Mr. Hen serves as a General Partner of Warburg Pincus & Co. and as a Managing Director and Member of Warburg Pincus LLC. Mr. Hen joined Warburg Pincus in 2000 and focuses on investments in biotechnology and pharmaceuticals. Prior to joining Warburg Pincus, he served as a management consultant at McKinsey & Company. Prior to joining McKinsey, Mr. Hen held positions at Merck in both Research & Development and Manufacturing. Mr. Hen is currently a director of Neurogen Corporation, WuXi PharmaTech (Cayman) Inc. and several private companies. Mr. Hen holds Masters of Business Administration from The Wharton School, an Master of Science in chemical engineering from the Massachusetts Institute of Technology and a Bachelor of Science in chemical engineering from the University of Delaware.
Leff, Jonathan Jonathan S. Leff has served as a member of the Board of Directors of Allos Therapeutics, Inc. since March 2005. Mr. Leff serves as a General Partner of Warburg Pincus & Co. and as a Managing Director and Member of Warburg Pincus LLC. Mr. Leff joined Warburg Pincus in 1996 and is responsible for the firm's investment efforts in biotechnology and pharmaceuticals. Prior to joining Warburg Pincus, he was a consultant at Oliver, Wyman & Co. Mr. Leff is currently a director of Inspire Pharmaceuticals, Inc., InterMune, Inc., ZymoGenetics, Inc. and several private companies. Mr. Leff received his A.B. in Government from Harvard College and his Masters of Business Administration from Stanford University Graduate School of Business.
Lynch, Timothy Timothy P. Lynch has served as a member of the Board of Directors of Allos Therapeutics, Inc. since November 2005. Mr. Lynch is a General Partner of Stonepine Capital, L.P., a life-science focused investment fund. From October 2005 through June 2008, Mr. Lynch was the President and Chief Executive Officer of NeuroStat Pharmaceuticals, a start-up specialty pharmaceutical company. From June 2005 through September 2005, Mr. Lynch was President and Chief Executive Officer of Vivo Therapeutics, Inc., a venture-backed specialty pharmaceuticals start-up. From October 2002 through June 2005, Mr. Lynch served as Chief Financial Officer of Tercica, Inc. From 1999 to June 2002, Mr. Lynch served as Chief Financial Officer of InterMune, Inc. He was involved with the initial public offerings of both biopharmaceutical companies. Previously, Mr. Lynch served as Director of Strategic Planning and as a pharmaceutical sales representative at Elan Corporation, plc, a pharmaceutical company. He started his career as an investment banker at Goldman, Sachs & Co. and Chase Securities, Inc. Mr. Lynch is a director of BioForm Medical, Inc., Insite Vision, Inc., and Nabi Biopharmaceuticals. Mr. Lynch received his Bachelor of Arts in economics from Colgate University and his Masters of Business Administration from the Harvard Graduate School of Business.
Latts, Jeffrey Dr. Jeffrey R. Latts, M.D. has served as a member of the Board of Directors of Allos Therapeutics, Inc. since April 2007. Since January 2007, Dr. Latts has been a self-employed consultant to the pharmaceutical industry. Previously, Dr. Latts served as Executive Vice President of Exelixis, Inc., a biotechnology company, from January 2006 to January 2007, and as Senior Vice President of Exelixis, Inc. from July 2001 to December 2005. He also served as Chief Medical Officer of Exelixis, Inc. from July 2001 to September 2006. Prior to that, Dr. Latts held key management positions with Berlex Laboratories, a pharmaceutical healthcare company, where he served as Chief Medical Officer from 1995 to 2001, and Vice President, Clinical Research and Development from 1990 to 2001. Prior to that, Dr. Latts served as Vice President of Clinical Research at Wyeth Ayerst Research, a division of Wyeth Laboratories. He began his career in the pharmaceutical industry with the Parke-Davis Pharmaceutical Division of Warner Lambert. In over 25 years in the pharmaceutical industry, Dr. Latts has been involved in numerous investigational new drug application submissions and has successfully initiated early to late stage clinical trials for multiple disease areas, including cancer, immunology, central nervous system and metabolic diseases. Dr. Latts received a Bachelor of Science in medicine and an Doctorate of Medicine from the University of Minnesota.
Stout, David David M. Stout has served as a member of the Board of Directors of Allos Therapeutics, Inc. since March 2009. Mr. Stout most recently served as President, Pharmaceuticals at GlaxoSmithKline, where he was responsible for the company's global pharmaceutical operations, from January 2003 to February 2008. From 1999 to January 2003, Mr. Stout served as President, U.S. Pharmaceuticals at GlaxoSmithKline. From 1996 to 1998, Mr. Stout served as President and Director, Sales and Marketing-U.S. for SmithKline Beecham. Prior to that, Mr. Stout was President of Schering Laboratories, a division of Schering-Plough Corporation, from 1994 to 1996. Mr. Stout also held various executive and sales and marketing positions with Schering-Plough Corporation from 1979, when he joined the company, until 1994. Mr. Stout is a director of Airgas, Inc. Mr. Stout received his Bachelor of Arts in biology from McDaniel College.

Basic Compensation

Name Fiscal Year Total
Hoffman, Stephen 370,542
Berns, Paul 2,091,600
Clark, David 466,600
Caruso, James 1,259,700
Graboyes, Marc 719,000
Bennett, Bruce --
Hen, Stewart --
Leff, Jonathan --
Lynch, Timothy --
Latts, Jeffrey --
Stout, David --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Hoffman, Stephen 626,971 3,490,248
Berns, Paul 0 0
Clark, David 0 0
Caruso, James 0 0
Graboyes, Marc 0 0
Bennett, Bruce 0 0
Hen, Stewart 0 0
Leff, Jonathan 0 0
Lynch, Timothy 0 0
Latts, Jeffrey 0 0
Stout, David 0 0

Insider Trading

Name Shares Traded Price
HOFFMAN STEPHEN J 45,428 $7.30
HOFFMAN STEPHEN J 45,428 $2.42
HOFFMAN STEPHEN J 45,429 $7.11
HOFFMAN STEPHEN J 45,429 $2.42
BERNS PAUL L 65,160 $7.00
HOFFMAN STEPHEN J 45,429 $2.42
HOFFMAN STEPHEN J 45,429 $6.76
HOFFMAN STEPHEN J 45,429 $6.78
HOFFMAN STEPHEN J 45,429 $2.42
HOFFMAN STEPHEN J 45,428 $2.42
HOFFMAN STEPHEN J 45,428 $6.64
HOFFMAN STEPHEN J 25,428 $6.54
HOFFMAN STEPHEN J 25,428 $2.42
BENNETT BRUCE K JR 211 $5.59
CAGNONI PABLO J 61,373 $0.00
CARUSO JAMES V 85,400 $8.13
BERNS PAUL L 342,000 $3.14
CARUSO JAMES V 85,400 $3.13
BERNS PAUL L 342,000 $8.24
BERNS PAUL L 8,000 $8.14
CARUSO JAMES V 14,600 $3.13
CARUSO JAMES V 14,600 $8.13
BERNS PAUL L 8,000 $3.14
CARUSO JAMES V 50,000 $3.13
CARUSO JAMES V 50,000 $7.79
» Full list on Insider Trading
view people for: